IDEX Corporation reported first‑quarter 2026 results on 29 April 2026, showing revenue of $886.9 million, up 9 % year‑over‑year, and net income of $120 million, a 25.7 % increase from the same period last year. Diluted earnings per share were $1.61, falling short of the consensus estimate of $1.77 by $0.16. Adjusted EBITDA reached $230.4 million, reflecting a 50‑basis‑point rise in margin to 26 %.
The company’s Health & Science Technologies segment drove the bulk of revenue growth, generating $398.4 million in sales. Momentum in data‑center and semiconductor markets also contributed to the top‑line expansion, offsetting any headwinds in legacy product lines.
While revenue and net income exceeded expectations, diluted EPS missed consensus. The miss is attributed to higher operating costs that partially offset the revenue gains, a common challenge for companies experiencing rapid growth in high‑margin segments.
Management raised its full‑year adjusted EPS guidance to $8.35–$8.55, up from the prior $8.15–$8.35 range, signaling confidence in continued demand and cost discipline.
The company reiterated its 80/20 operating philosophy, emphasizing a focus on high‑growth, high‑margin opportunities to drive margin expansion and capital efficiency.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.